Transformative insights from discovery to clinic
We believe we can dramatically improve human health by deciphering biological complexity.

- Next-generation proteomics is revolutionizing life sciences and targeted therapies
- Industry-leading depth and scalability that unlocks full, unbiased access to the functional proteome
- Heritage of invention and innovation backed by a world-class scientific and entrepreneurial leadership
At the Vanguard of Breakthrough

Huge opportunity for applying deep proteomics data and insights
Proteomics decodes the realities of a disease

Proteomics bridges the static information provided by genomics of “what could be,” with the context to understand what’s actually happening, right now, so disease can be treated.

**GENOME**

~20,000 protein-encoding genes that provide a static view of health risks

Less functional information

**PROTEOTYPE**

~1 million protein variants that are dynamic indicators based on environment and inherited genes

More functional information

**PHENOTYPE**

Physical indicator of health and disease
Proteomics addresses impediments to precision medicine

Proteomics’ greatest potential lies in the targeted drug space, where the vast majority of druggable targets are unaccounted for, and matching the right patients with the right drug targets is challenging.
Powering precision medicine into reality

Biognosys can decode proteomics insights that will transform the development of new targeted therapies.

Biognosys discovered novel protein targets of an exploratory compound using proprietary structural proteomics technology.

(Data published in peer-reviewed journal in collaboration with AstraZeneca)

Biognosys identified a novel proteomic signature that predicts clinical outcome to immunotherapy.

(Data presented at ESMO 2020 in collaboration with Institut Curie)
Different subsets of pancreatic cancer patients may be more likely to respond to chemo and PD-1 versus chemo and CD40. Our findings provide clues on how to best identify these patients.

Theresa LaVallee, PhD
Former Vice President, Translational Medicine and Regulatory Affairs
Parker Institute for Cancer Immunotherapy

Recent advances in proteomics help us explore complex diseases to identify novel targets for intervention. In NASH, the need is so great, the population so diverse and the timing is perfect.

Julia Wattacheril, MD MPH
Nonalcoholic Fatty Liver Disease Program Director
Columbia University Irving Medical Center
Not All Proteomics Are Created Equal

Actionable insights born from an unbiased approach to discovery
The road to gold standard

Gold standard technology must check all of these boxes

- DEEP COVERAGE
- UNBIASED, UNIVERSAL ANALYSIS
- MULTI-DIMENSIONAL INSIGHTS
Biognosys leads with the deepest proteomics technology

We can measure more proteins than anyone else with >13,800 proteins in cells and tissues and >4,200 proteins in plasma.
Unbiased, universal detection without limits

Affinity-based methods have a limited view

Biognosys can see it all

Biognosys’ unique technology – even among other mass-spec approaches – is not influenced by what we know, but instead analyzes and reveals the whole proteome in any sample type from any species.
Our view is as multi-dimensional as cellular functions

Affinity reagents cover only small epitope sites per protein.

Biognosys covers many more parts of the protein and its proteoforms.

- **PROTEIN QUANTIFICATION**
- **PROTEIN STRUCTURE**
- **POST-TRANSLATIONAL MODIFICATIONS**
- **PROTEIN INTERACTIONS**

We can also unravel other aspects of the proteome.

Affinity reagents cover only small epitope sites per protein.

Biognosys covers many more parts of the protein and its proteoforms.

Covered sequence (extrapolation)

Covered sequence

Covered regions of known genetic variation
Biognosys Leadership in Proteomics

Next-generation proteomics solutions built on heritage of invention and innovation
Biognosys by the numbers

- > 13 Years of proteomics innovation
- > 1 Billion Data points generated each year
- > 800 Clients; 19 of the top 20 pharmaceutical companies
- > 2,000 Scientific publications
- > 1,600 Samples per day — Largest high-end facility in the world
- > 20 Granted patents
Our Collaborators

Strategic Collaborators

Scientific Collaborators
We make the proteome accessible by covering the widest range of researchers’ needs

Mission

We enable life science researchers and drug hunters to unlock true discoveries by looking at the proteome from every angle. We push the boundaries of what is possible with our proteomics solutions to improve human health.

Services

State-of-the-art **high-throughput facility**, the largest of its kind in the world

Software

- Data-Independent Acquisition (DIA)
- Targeted Proteomics
- Data-Dependent Acquisition (DDA)
- Quality Control
- AI-empowered software solutions for streamlined data analytics

Kits

- Peptide Kits for Quantification
- Peptide Kits for Quality Control
- Sample Preparation Kits
- Ready-to-use kits for absolute quantification
Biognosys’ solutions are used by clients across all phases from research to clinical trials

Enabling researchers to accelerate and de-risk drug discovery and development.

- Discovery Biology
  - Target Deconvolution
  - Mechanism of Action
  - Target Validation, Novel
  - Target Discovery
  - Disease Biology Profiling

- Preclinical Studies
  - Animal Model Profiling
  - Translational Biomarker Discovery
  - Validation of Protein Expression
  - Toxicity Profiling

- Early & Late Clinical Studies
  - Biomarker discovery in:
    - Blood
    - CSF
    - Urine
    - Tissues

- Population health screening
  - Patients Stratification
  - Disease Insights Generation
  - Novel Drug Target Discovery
  - Identification of Prognostic and Predictive Biomarkers
Biognosys is well-cited in the scientific literature

Co-authored multiple publications in high-impact, peer-reviewed journals.
Experienced executive management supported by leading proteomics experts

Executive Management

Oliver Rinner, PhD
Co-founder, CEO

Lukas Reiter, PhD
Chief Technology Officer

Kristina Beeler, PhD
Chief Business Officer

Karel Novy, PhD
Chief Operating Officer

Lidia Novak, CFA
Chief Financial Officer

Scientific Advisory Board

Prof. Ruedi Aebersold
Co-founder, ETH Zurich

Prof. Paula Picotti
ETH Zurich

Prof. Johan Malmstroem
Co-founder, Lund University
TRANSFORMATIVE INSIGHTS FROM DISCOVERY TO CLINIC